M2 PHARMA-December 8, 2010-A-CUBE, Wakunaga Pharmaceutical enter into agreement on monoclonal
therapeutic antibody(C)2010 M2 COMMUNICATIONS
While this technique has generated monoclonals
, there is a limiting factor: The antibody in question has to be against a fairly benign substance so that a person could be vaccinated with it.
difficile Toxin A and Toxin B monoclonal
Researchers studying this and other cancers have long sought to use monoclonal
antibodies -- biological molecules that bind only to particular target cells -- to attack tumors directly or to shuttle toxins selectively to cancer cells.